We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Biosensing Technology Can Detect Aβ-Binding Exosomes in Blood

Two test tubes of blood held by a gloved hand in a laboratory.
Credit: Pixabay

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Biosensing Technology Can Detect Aβ-Binding Exosomes in Blood"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Researchers from Hokkaido University and Toppan have developed a method to detect build-up of amyloid beta in the brain, a characteristic of Alzheimer's disease, from biomarkers in blood samples.


Alzheimer's disease is a neurodegenerative disease, characterised by a gradual loss of neurons and synapses in the brain. One of the primary causes of Alzheimer's disease is the accumulation of amyloid beta (Aβ) in the brain, where it forms plaques. Alzheimer's disease is mostly seen in individuals over 65 years of age, and cannot currently be stopped or reversed. Thus, Alzheimer's disease is a major concern for nations with ageing populations, such as Japan.


A team of scientists from Hokkaido University and Toppan, led by Specially Appointed Associate Professor Kohei Yuyama at the Faculty of Advanced Life Science, Hokkaido University, have developed a biosensing technology that can detect Aβ-binding exosomes in the blood of mice, which increase as Aβ accumulates in the brain. 


When tested on mice models, the Aβ-binding exosome Digital ICATM (idICA) showed that the concentration of Aβ-binding exosomes increased with the increase in age of the mice. This is significant as the mice used were Alzheimer's disease model mice, where Aβ builds up in the brain with age.


In addition to the lack of effective treatments of Alzheimer's, there are few methods to diagnose Alzheimer's. Alzheimer's can only be definitively diagnosed by direct examination of the brain – which can only be done after death. Aβ accumulation in the brain can be measured by cerebrospinal fluid testing or by positron emission tomography; however, the former is an extremely invasive test that cannot be repeated, and the latter is quite expensive. Thus, there is a need for a diagnostic test that is economical, accurate and widely available.


Previous work by Yuyama's group has shown that Aβ build-up in the brain is associated with Aβ-binding exosomes secreted from neurons, which degrade and transport Aβ to the microglial cells of the brain. Exosomes are membrane-enclosed sacs secreted by cells that possess cell markers on their surface. The team adapted Toppan's proprietary Digital Invasive Cleavage Assay (Digital ICATM) to quantify the concentration of Aβ-binding exosomes in as little as 100 µL of blood. The device they developed traps molecules and particles in a sample one-by-one in a million micrometer-sized microscopic wells on a measurement chip and detects the presence or absence of fluorescent signals emitted by the cleaving of the Aβ-binding exosomes.


Clinical trials of the technology are currently underway in humans. This highly sensitive idICA technology is the first application of ICA that enables highly sensitive detection of exosomes that retain specific surface molecules from a small amount of blood without the need to learn special techniques; as it is applicable to exosome biomarkers in general, it can also be adapted for use in the diagnosis of other diseases.


Reference: Yuyama K, Sun H, Igarashi Y, et al. Immuno-digital invasive cleavage assay for analyzing Alzheimer’s amyloid ß-bound extracellular vesicles. Alzheimer’s Res Ther. 2022;14(1):140. doi: 10.1186/s13195-022-01073-w


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.


Advertisement